
Jan 12 (Reuters) - Bicara Therapeutics Inc BCAX.O:
BICARA THERAPEUTICS ANNOUNCES PHASE 3 OPTIMAL DOSE AND PROVIDES 2026 CORPORATE OUTLOOK
BICARA THERAPEUTICS - EXPECTS TO ACHIEVE SUBSTANTIAL ENROLLMENT IN FORTIFI-HN01 IN 2026 TO ENABLE INTERIM ANALYSIS IN MID-2027
BICARA THERAPEUTICS INC - ANTICIPATES MULTIPLE DATA READOUTS IN 2026 FOR FICERAFUSP ALFA